Credit Suisse analyst Judah Frommer lowered the firm’s price target on Stoke Therapeutics to $32 from $38 and keeps an Outperform rating on the shares. The analyst notes Stoke reiterated incremental STK-001 data from AES 2022 during management’s presentation at the 2023 JPMorgan healthcare conference, provided insight on ‘001’s evolving dosing/safety profile, and shared go-forward plans for ‘001 and ‘002.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STOK:
- Stoke Therapeutics downgraded to Underperform from Buy at BofA
- Stoke Therapeutics price target lowered to $35 from $70 at H.C. Wainwright
- Stoke Therapeutics announces highlights from STK-001 presentation
- Stoke Therapeutics (NASDAQ: STOK) Crashes over 20% after Releasing Early Trial Data
- Stoke Therapeutics reports Q3 EPS (66c), consensus (68c)
